Clinical Trial Detail

NCT ID NCT02324582
Title MK-3475/BCG in High Risk Superficial Bladder Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Southern Illinois University
Indications

bladder urothelial carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.